Evidence strength for the context described on this page.
PEPTIDE ATLAS / MUSCLE & RECOVERY / CJC-1295
Not FDA-approvedEarly human
CJC-1295
ALSO KNOWN ASCJC-1295 with DAC · without DAC
A growth-hormone-releasing hormone analog with limited early studies and no approved wellness use.
01CATEGORYMuscle & recovery
02REGULATORY STATUSNot FDA-approved
03COMMON ROUTESubcutaneous injection in human research and clinic marketing
04DOSE BASISHuman studies + reported clinic use
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read limits before dose
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
RESEARCH PASSPORT
The five facts to know first.
REVIEWED
JULY 2026
Status is product-, formulation- and indication-specific.
Trial, label or reported-practice basis is always named.
Official labels, regulators, trials and indexed literature where available.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗OVERVIEW
What CJC-1295 is.
A synthetic GHRH analog. Products labeled 'with DAC' and 'without DAC' have materially different pharmacology, yet marketing often treats them as one interchangeable peptide.
HOW IT IS THOUGHT TO WORK
Stimulates pituitary GH release and can increase circulating IGF-1. The drug-affinity-complex version is designed for longer action.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Early studies show GH and IGF-1 elevation
- No established improvement in muscle, recovery, sleep or longevity in healthy adults
- Clinically meaningful lean-mass gain
- Anti-aging
- Injury repair
- Safety of long-term combination with ipamorelin
Evidence grade: Early human. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
DOSAGE CONTEXT
Best available dosing range.
Human studies + reported clinic useBest human-research range for authentic CJC-1295 with DAC: single subcutaneous doses of 30–60 mcg/kg and repeated doses around 20–30 mcg/kg weekly. Clinics more commonly publish 1–2 mg once or twice weekly for the DAC form. 'CJC without DAC' is modified GRF 1-29—a different short-acting molecule commonly listed at 100–200 mcg once or twice daily. Neither clinic regimen is FDA approved.
BEST AVAILABLE GENERIC RANGE
Men and women.
The basis is named above. Reported-use ranges describe what clinics or communities publish; they are not proof of safety, efficacy, legality or product quality.
- Schedule in that source context
- With DAC is usually reported weekly because of prolonged exposure; without DAC is reported once or twice daily, often near bedtime. Common clinic cycles run roughly 8–12 weeks.
- How to interpret it
- Confirm the exact molecule. CJC-1295 with DAC and modified GRF 1-29 are not interchangeable. Human research established hormone exposure—not muscle, recovery, sleep or longevity benefit.
ACTUAL HUMAN DOSES REPORTED IN THE RECORD
Research regimens may use different routes, diagnoses, formulations and monitoring. They cannot automatically be converted into a general protocol.
- Healthy-adult dose-escalation research: single subcutaneous CJC-1295 with DAC doses of 30 or 60 mcg/kg produced prolonged GH and IGF-1 increases.
- Repeated-dose research: approximately 20–30 mcg/kg subcutaneously once weekly for 2–3 doses.
- Route
- Subcutaneous injection in human research and clinic marketing
- Duration
- Human studies were short; reported clinic cycles are commonly 8–12 weeks
- Men & women
- No validated sex-specific regimen. IGF-1 response, age, glucose tolerance and comorbidities matter more than a generic male/female split.
Clinician verification required. Always double-check the exact molecule or salt, concentration, route, volume, schedule, indication, patient-specific contraindications, interactions and applicable law with the prescribing clinician and dispensing pharmacy. A disclaimer does not make an unapproved product FDA-approved, and a reported-use range is not a prescription.
MONITORING
What should be tracked.
- IGF-1 does not prove clinical benefit
- Glucose, edema and blood pressure would require clinician oversight in any legitimate study
SAFETY
Risks, red flags and reasons to avoid it.
- FDA reports increased heart rate and systemic vasodilatory reactions
- Potential edema, glucose intolerance and GH/IGF-1-related adverse effects
- Immunogenicity and impurities
- Unknown malignancy risk with chronic growth signaling
- Active malignancy
- Uncontrolled diabetes
- Pregnancy
- Stacking multiple GH secretagogues
Stop and seek careGet urgent medical help for trouble breathing, facial or throat swelling, chest pain, fainting, severe persistent abdominal pain, neurologic changes, severe hypoglycemia, uncontrolled vomiting or a prolonged painful erection.
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
PRIMARY SOURCES
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. A source supports the specific statement beside it—not every claim made about the molecule.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Not FDA-approved; sold by gray-market vendors and some clinics.
A measurable hormone change is a surrogate signal—not proof that a consumer feels better, gains useful muscle or lives longer.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP